Carfilzomib-Induced Thrombotic Microangiopathy Treated with Eculizumab: A Case Report and Rapid Literature Review
Background: Thrombotic microangiopathies (TMAs) can be induced by drugs. Recent works have indicated proteasome inhibitors, including carfilzomib, as a possible new causative agent. Although the physiopathology and management of carfilzomib-induced TMA are still unknown, eculizumab seems to be effic...
Saved in:
Main Authors: | Federica Pallotti (Author), Claire Queffeulou (Author), Mathieu Bellal (Author), Bastien Jean-Jacques (Author), Anne-Claire Gac (Author), Valérie Chatelet (Author), Annabel Boyer (Author), Victor Gueutin (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
by: Jihad Ben Gabr MD, et al.
Published: (2020) -
Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022) -
Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
by: Laura Gomez-Ganda, et al.
Published: (2021) -
A Case Report of Quinine-Induced Thrombotic Microangiopathy Successfully Treated With Eculizumab
by: Jun Yen Ng BMedSci (Hons), et al.
Published: (2024) -
COVID-19 and thrombotic microangiopathy
by: E. V. Sluhanchuk, et al.
Published: (2022)